Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CEST
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
06/23 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Other Events
06/23 SCICLONE PHARMACEUTICALS INC : Other Events (form 8-K)
06/19 Brower Piven Commences an Investigation into the Proposed Sale of SciClone Ph..
06/19 SCICLONE INVESTOR ALERT BY THE FORME : Kahn Swick & Foti, LLC Investigates Adequ..
06/15 Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whethe..
06/13 Brower Piven Commences an Investigation into the Proposed Sale of SciClone Ph..
06/13 SCICLONE PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation..
06/13 Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale ..
06/09 SCICLONE PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
06/08 SCICLONE PHARMACEUTICALS : Enters Into Definitive Merger Agreement To Be Acquire..
More news
News from SeekingAlpha
06/09 RISK ARBITRAGE TODAY : Yahoo, Pandora And An M&A Fund That Has 20% In One Stock
06/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/08 PREMARKET GAINERS AS OF 9 : 05 am
06/08 SciClone Pharma to be acquired by Chinese consortium for $605M; shares up 7% ..
05/10 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q1 2017 Results - Ea..
Financials ($)
Sales 2017 174 M
EBIT 2017 51,1 M
Net income 2017 49,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 11,70
P/E ratio 2018 10,28
Capi. / Sales 2017 3,28x
Capi. / Sales 2018 3,07x
Capitalization 569 M
Chart SCICLONE PHARMACEUTICALS,
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Technical analysis trends SCICLONE PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 14,0 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Cheung Chief Financial Officer & Senior VP-Finance
Richard J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICALS, INC.1.85%569
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303